meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
2
mHNSCC - L1 - PDL1 positive
4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
4
mHNSCC - L2 - PDL1 negative
2
mHNSCC - L2 - PDL1 positive
1
hepatocell cancer (HCC)
1
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus 5FU plus platin
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs HER inhibitor
vs EGFR inhibitor
vs cetuximab based chemotherapy
vs cetuximab plus platin plus 5FU
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs tremelimumab
vs anti-PD-(L)1
vs durvalumab based treatment
vs durvalumab alone
All patients
Age < 65y (younger)
Age > 65y
Age > 75y (older)
Asian type
cancer type (metastatic)
cancer type (recurrent)
ECOG 0
ECOG 1
Gender, female
Gender, male
P16 negative (HPV)
P16 positive (HPV)
PD-L1 < 1%
PD-L1 < 10%
PD-L1 < 5%
PD-L1 > 1%
PD-L1 > 10%
PD-L1 > 5%
PDL1 (CPS < 1)
PDL1 (CPS >1)
PDL1 (TC0 and IC0 : <1% of TC and IC)
PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC)
PDL1 (TPS <50%)
PDL1 (TPS >50%)
PDL1 < 25%
PDL1 >25%
smoker (current or former)
smoker (Current)
smoker (Former)
smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DCR
deaths (OS)
deaths (OS) (extension)
DOR
objective responses (ORR)
objective responses (ORR) (extension)
PFS (extension)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE (grade 3-5)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
SAE (any grade)
STRAE (any grade)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Acute kidney injury TRAE (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Blood and lymphatic system disorders TRAE (grade 3-4)
Blood creatinine increased TRAE (grade 3-4)
Cardiac disorders TRAE (grade 3-4)
Chills TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Cough TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Dermatitis acneiform TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Dyspepsia TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Eczema TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Epistaxis TRAE (grade 3-4)
Erythema TRAE (grade 3-4)
Eye disorders TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Febrile neutropenia TRAE (grade 3-4)
Gastritis TRAE (grade 3-4)
Gastrointestinal disorders TRAE (grade 3-4)
General disorders and administration site conditions TRAE (grade 3-4)
Guillain-Barré syndrome TRAE (grade 3-4)
Headache TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hepatobiliary disorders TRAE (grade 3-4)
Hypersensitivity TRAE (grade 3-4)
Hypertension TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Metabolism and nutrition disorders TRAE (grade 3-4)
Mucosal inflammation TRAE (grade 3-4)
Musculoskeletal and connective tissue disorders TRAE (grade 3-4)
Myalgia TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Nervous system disorders TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Pancytopenia TRAE (grade 3-4)
Paraesthesia TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Peripheral oedema TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritic rash TRAE (grade 3-4)
Pruritus generalised TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Renal and urinary disorders TRAE (grade 3-4)
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4)
Sepsis TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Skin and subcutaneous tissue disorders TRAE (grade 3-4)
Skin exfoliation TRAE (grade 3-4)
Stevens-Johnson syndrome TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Urticaria TRAE (grade 3-4)
Uveitis TRAE (grade 3-4)
Vascular disorders TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Weight decreased TRAE (grade 3-4)
Abdominal pain AE (grade 3-4)
Acute kidney injury AE (grade 3-4)
Anaemia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Blood and lymphatic system disorders AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dizziness AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Febrile neutropenia AE (grade 3-4)
Gastrointestinal disorders AE (grade 3-4)
General disorders and administration site conditions AE (grade 3-4)
Hypertension AE (grade 3-4)
Hypothyroidism AE (grade 3-4)
Increase AST AE (grade 3-4)
Leucopenia AE (grade 3-4)
Metabolism and nutrition disorders AE (grade 3-4)
Mucosal inflammation AE (grade 3-4)
Nausea AE (grade 3-4)
Nervous system disorders AE (grade 3-4)
Neutropenia AE (grade 3-4)
Pneumonitis AE (grade 3-4)
Rash AE (grade 3-4)
Renal and urinary disorders AE (grade 3-4)
Respiratory, thoracic and mediastinal disorders AE (grade 3-4)
Sepsis AE (grade 3-4)
Skin and subcutaneous tissue disorders AE (grade 3-4)
Stomatitis AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Vascular disorders AE (grade 3-4)
Vomiting AE (grade 3-4)
Weight decreased AE (grade 3-4)
DCR
mHNSCC - L1 - all population
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
versus cetuximab plus platin plus 5FU
pembrolizumab alone vs. cetuximab plus platin plus 5FU
1
-
pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU
1
-
mHNSCC - L1 - PDL1 positive
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - 1st line (L1)
mHNSCC - L1 - PDL1 positive
versus cetuximab plus platin plus 5FU
pembrolizumab alone vs. cetuximab plus platin plus 5FU
2
-
pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU
2
-
mHNSCC - L2 - all population
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
versus Standard of Care (SoC)
durvalumab alone vs. Standard of Care (SoC)
1
certainty unassessable
0%
durvalumab plus tremelimumab vs. Standard of Care (SoC)
1
certainty unassessable
+12%
nivolumab alone vs. Standard of Care (SoC)
1
-
pembrolizumab alone vs. Standard of Care (SoC)
1
-
mHNSCC - L2 - PDL1 negative
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - 2nd line (L2)
mHNSCC - L2 - PDL1 negative
versus durvalumab alone
durvalumab plus tremelimumab vs. durvalumab alone
1
certainty unassessable
-41%
versus tremelimumab
durvalumab plus tremelimumab vs. tremelimumab
1
certainty unassessable
+841%
mHNSCC - L2 - PDL1 positive
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - 2nd line (L2)
mHNSCC - L2 - PDL1 positive
versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC)
1
-
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open